A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Heart Disease (CHD), CHD Risk Equivalents...

Project: Research

Status	Finished
Effective start/end date	11/7/12 → 11/6/13

Project Details